A Phase 1 interventional study of HS-10506, Itraconazole in Healthy Participants, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A single-center, open-label, fixed-sequence, self-controlled phase I clinical trial aimed at evaluating the effect of itraconazole capsules(CYP3A inhibitor) on the pharmacokinetics of HS-10506 tablets in healthy participants.
On Day 1 and Day 11 of the trial, HS-10506 tablets will be orally administered under fasting conditions in the morning. From Day 7 to Day 15, itraconazole capsules (0.2 g, administered as two 0.1 g capsules) will be taken orally once daily for nine consecutive days. On the morning of Day 11, itraconazole capsules and HS-10506 tablets will be taken concurrently. When administered alone or in combination with itraconazole capsules, HS-10506 tablets will be given under fasting conditions. When administered alone, itraconazole capsules will be taken within 15 minutes after a meal, with approximately 240 mL of water.
Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug-drug interaction Arm
Drug: HS-10506, Itraconazole
Drug pages: HS-10506 · Itraconazole
HS-10506: Administered under fasting conditions in the morning. Itraconazole: Itraconazole capsules (0.2 g) are taken orally once daily for nine consecutive days.
Evaluation of PK parameters of HS-10506: Cmax
To evaluate the Cmax of HS-10506 administered alone and in combination with Itraconazole in healthy participants.
Time frame: 120 hours after administration of HS-10506
Evaluation of PK parameters of HS-10506: AUC0-t
To evaluate the AUC0-t of HS-10506 administered alone and in combination with Itraconazole in healthy participants.
Time frame: 120 hours after administration of HS-10506
Evaluation of PK parameters of HS-10506: AUC0-∞
To evaluate the AUC0-∞ of HS-10506 administered alone and in combination with Itraconazole in healthy participants.
Time frame: 120 hours after administration of HS-10506
Evaluation of PK parameters of HS-10506:Tmax
To evaluate the Tmax of HS-10506 administered alone and in combination with Itraconazole in healthy participants.
Time frame: 120 hours after administration of HS-10506
Evaluation of PK parameters of HS-10506: t1/2z
To evaluate the t1/2z of HS-10506 administered alone and in combination with Itraconazole in healthy participants
Time frame: 120 hours after administration of HS-10506
Evaluation of PK parameters of HS-10506: λz
To evaluate the λz of HS-10506 administered alone and in combination with Itraconazole in healthy participants.
Time frame: 120 hours after administration of HS-10506
Evaluation of PK parameters of HS-10506: CL/F
To evaluate the CL/F of HS-10506 administered alone and in combination with Itraconazole in healthy participants.
Time frame: 120 hours after administration of HS-10506
Evaluation of PK parameters of HS-10506: Vz/F
To evaluate the Vz/F of HS-10506 administered alone and in combination with Itraconazole in healthy participants.
Time frame: 120 hours after administration of HS-10506
Evaluation of PK parameters of HS-10506: MRT0-t
To evaluate the MRT0-t of HS-10506 administered alone and in combination with Itraconazole in healthy participants.
Time frame: 120 hours after administration of HS-10506
Evaluation of PK parameters of HS-10506: MRT0-∞
To evaluate the MRT0-∞ of HS-10506 administered alone and in combination with Itraconazole in healthy participants.
Time frame: 120 hours after administration of HS-10506
Adverse events
To evaluate the adverse events (AEs) of HS-10506 administered alone and in combination with Itraconazole in healthy participants.
Time frame: through study completion, an average of 36 days
blood pressure
To evaluate the blood pressure of HS-10506 administered alone and in combination with Itraconazole in healthy participants.
Time frame: through study completion, an average of 36 days
Pulse
To evaluate the Pulse of HS-10506 administered alone and in combination with Itraconazole in healthy participants
Time frame: through study completion, an average of 36 days
body temperature
To evaluate the body temperature of HS-10506 administered alone and in combination with Itraconazole in healthy participants.
Time frame: through study completion, an average of 36 days
oxygen saturation
To evaluate the oxygen saturation of HS-10506 administered alone and in combination with Itraconazole in healthy participants
Time frame: through study completion, an average of 36 days
complete blood count (CBC)
To evaluate the abnormal of complete blood count (CBC)of HS-10506 administered alone and in combination with Itraconazole in healthy participants.
Time frame: through study completion, an average of 36 days
urinalysis
To evaluate the abnormal of urinalysis of HS-10506 administered alone and in combination with Itraconazole in healthy participants.
Time frame: through study completion, an average of 36 days
blood chemistry
To evaluate the abnormal of blood chemistry of HS-10506 administered alone and in combination with Itraconazole in healthy participants.
Time frame: through study completion, an average of 36 days
coagulation tests
To evaluate the abnormal of coagulation tests of HS-10506 administered alone and in combination with Itraconazole in healthy participants.
Time frame: through study completion, an average of 36 days
thyroid function test (TFT)
To evaluate the abnormal of thyroid function test (TFT) of HS-10506 administered alone and in combination with Itraconazole in healthy participants.
Time frame: through study completion, an average of 36 days
Physical examination (include skin, mucous membranes and lymph nodes; head and neck; chest; abdomen; spine and extremities; nervous system, etc)
To evaluate the abnormal of physical examination of HS-10506 administered alone and in combination with Itraconazole in healthy participants.
Time frame: through study completion, an average of 36 days
12-lead electrocardiogram (include heart rate, PR, RR, QRS duration, QT interval and QTcF)
To evaluate the abnormal of 12-lead electrocardiogram of HS-10506 administered alone and in combination with Itraconazole in healthy participants.
Time frame: through study completion, an average of 36 days
Start is estimated for Apr 2026; primary completion for Jul 2026, 3 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: HS-10506 · Itraconazole
Jiangsu Hansoh Pharmaceutical Co., Ltd. →